Trial Profile
A Cross-Sectional Study of Patients with Chronic Immune Thrombocytopenic Purpura and Caregivers to Estimate the Proportion who Administer Romiplostim Correctly After Receipt of Home Administration Training Materials
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2018
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Amgen
- 19 Sep 2018 Primary endpoint (Correct administration of romiplostim) has been met, as per the results published in the Drug Safety
- 19 Sep 2018 Results published in the Drug Safety
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management